Foghorn Therapeutics Inc. (FHTX) has been beaten down lately with too much selling pressure. While the stock has lost 23.1% ...

Foghorn Therapeutics Inc. (FHTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

First-in-class oral selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784), advancing in Phase 1 trial for SMARCA4 mutated cancers, with ...

Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. Foghorn Therapeutics Inc ...

Foghorn Therapeutics on Monday said it is ending independent development of its FHD-286 drug candidate following disappointing results from an early-stage study. Foghorn said the objective ...

The foghorn rang in the New Year to Madisonians again from the bell tower atop the Hartley Dodge Memorial at midnight ...

Foghorn Therapeutics (FHTX) announced its strategic objectives for 2025. First-in-class oral selective SMARCA2 inhibitor, FHD-909, advancing in ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting ...